Company Overview and News

27
BIOC / Biocept, Inc. BIOC-DEF14A-20180529

2018-05-29 sec.gov
bioc-def14a_20180529.htm UNITED STATES
BIOC

17
BIOC / Biocept, Inc. S-1

2018-05-28 sec.gov
bioc-def14a_20180523.htm As filed with the Securities and Exchange Commission on May 23, 2018
BIOC

39
BIOC / Biocept, Inc. BIOC-424B3-20180524 (Prospectus)

2018-05-25 sec.gov
bioc-424b3.htm This filing is made pursuant to Rule 424(b)(3)
BIOC

38
BIOC / Biocept, Inc. BIOC-PRE14A-20180524

2018-05-17 sec.gov
bioc-pre14a_20180628.htm UNITED STATES
BIOC

19
BIOC / Biocept, Inc. BIOC-8K-20180515 (Current Report)

2018-05-17 sec.gov
bioc-8k_20180515.htm
BIOC

23
Biocept's (BIOC) CEO Michael Nall on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Biocept First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. [Operator Instructions]
TMO BIOC

25
BIOC / Biocept, Inc. BIOC-10Q-20180331 (Quarterly Report)

2018-05-15 sec.gov
bioc-10q_20180331.htm UNITED STATES
BIOC

53
BIOC / Biocept, Inc. FORM S-3

2018-05-15 sec.gov
bioc-8k_20180515.htm As filed with the Securities and Exchange Commission on May 15, 2018
BIOC

36
BIOC / Biocept, Inc. BIOC-10K/A1-20171231 (Annual Report)

2018-04-30 sec.gov
bioc-10ka_20171231.htm
BIOC

23
BIOC / Biocept, Inc. BIOC-8K-20180404 (Current Report)

2018-04-06 sec.gov
bioc-8k_20180403.htm UNITED STATES
BIOC

30
Biocept's (BIOC) CEO Michael Nall on Q4 2017 Results - Earnings Call Transcript

2018-03-29 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Biocept Fourth Quarter and Full Year 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session [Operator Instructions]. As a reminder, this conference call is being recorded today, March 28, 2018.
TMO BIOC FMI GHDX

17
BIOC / Biocept, Inc. BIOC-10K-20171231 (Annual Report)

2018-03-28 sec.gov
bioc-10k_20171231.htm
BIOC

17
BIOC / Biocept, Inc. BIOC-8K-20180328 (Current Report)

2018-03-28 sec.gov
bioc-8k_20180328.htm
BIOC

BIOC : Biocept Stock Analysis and Research Report

2017-10-16 - Asif

Biocept is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” its current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic mutations that may qualify a subset of cancer patients for targeted therapy. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. Biocept assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Biocept current assays and planned future assays focus on key solid tumor indications utilizing its Target-Selectors liquid biopsy technology platform for the biomarker anal...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to BIOC / Biocept, Inc. on message board site Silicon Investor.

Biocryst Pharmaceuticals Inc (BCRX) Enzo Biochemical Inc. A biotechnology Co. with earnings.
Biocurex BIOCUREX INC (BOCX)
Biocryst Pharmaceuticals (BCRX) BCRX: BioCryst Pharmaceuticals
BICO: Biocontrol Technology Inc Biochem Pharma (BCHE)
Biocontrol Technology (BICO) Biocontrol Inc.
CUSIP: 09072V105